The new market access environment is value-driven. With shrinking health budgets – the drug budget is being more heavily scrutinised than ever before. To guarantee access, payers and HTA agencies need to know exactly what medicines will do in the ‘real world’ – EVEN with orphan drugs where small patient populations make evidence hard to come by. That's why eyeforpharma have commissioned the exclusive whitepaper Real World Data: Sources & Applications
Fill in your details on the right to get the Real World Data Whitepaper sent straight to your inbox
Taken from interviews and in-depth insights from senior thought leaders from Janssen, Amgen, CPRD, UBC and the author of ‘The Future of Health Economics’ you will gain an understanding of:
Fill in your details on the right to get the whitepaper sent straight to your inbox
Would love to know what you think of it.